Established more than three decades ago, Kamada is a global biopharmaceutical company focused on innovative specialty – hyperimmune globulin therapies to save and improve lives of patients with limited treatment alternatives.
Our Strength is in Hyperimmune Therapy
Kamada's primary focus is on solid organ transplant recipients and individuals at high risk of contracting infectious diseases. We have a broad hyperimmune portfolio, with 5 FDA-approved immunoglobulin (IgG) products and the unique ability to rapidly develop new hyperimmune plasma IgG therapies.
Committed to Improved Patient Outcomes
We invest in scientific innovation and foster strong partnerships within the transplant community in an effort to improve the lives of transplant recipients.